# TMC207 +/- Rifabutin/Rifampin

> **NCT01341184** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 33 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifabutin
- **DRUG:** Rifampin
- **DRUG:** TMC207

## Key facts

- **NCT ID:** NCT01341184
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-21
- **Primary completion:** 2012-05-23
- **Final completion:** 2012-05-23
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01341184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01341184, "TMC207 +/- Rifabutin/Rifampin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01341184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*